Payment overview · 2025
General Payments
$1,315.04
2 reported records · 2 companies
Healthcare provider profile · identity verified
Steven A Yarows, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CHELSEA, MI · NPI 1275532087
Verified facts
What the public records show
CMS Open Payments records show Steven A Yarows, MD received $1,315.04 in general payments during 2025 across 2 reported records.
Baxter Healthcare accounted for 93.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Baxter Healthcare | Unresolved — no canonical attribution shown | $1,225.00 | 93.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $90.04 | 6.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $1,225.00 | 1 |
| Food and Beverage | $90.04 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Hillrom - ABPM 6100 Blood Pressure Monitor Normalized: hillrom abpm 6100 blood pressure monitor |
Device | Baxter Healthcare | $1,225.00 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Blood Pressure Connector Normalized: hillrom blood pressure connector |
Device | Baxter Healthcare | $1,225.00 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Connex ProBP 3400 Digital Blood Pressure Device Normalized: hillrom connex probp 3400 digital blood pressure device |
Device | Baxter Healthcare | $1,225.00 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - FlexiPort Disposable Blood Pressure Cuffs Normalized: hillrom flexiport disposable blood pressure cuffs |
Device | Baxter Healthcare | $1,225.00 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Welch Allyn Home Blood Pressure Monitor Normalized: hillrom welch allyn home blood pressure monitor |
Device | Baxter Healthcare | $1,225.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 790 | 224 |
| Amlodipine Besylate | Amlodipine Besylate | 603 | 178 |
| Irbesartan | Irbesartan | 495 | 141 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 440 | 134 |
| Lisinopril | Lisinopril | 371 | 107 |
| Levothyroxine Sodium | Levothyroxine Sodium | 346 | 79 |
| Pravastatin Sodium | Pravastatin Sodium | 300 | 80 |
| Metformin Hcl | Metformin Hcl | 282 | 78 |
| Pioglitazone Hcl | Pioglitazone Hcl | 278 | 81 |
| Omeprazole | Omeprazole | 262 | 76 |
| Spironolactone | Spironolactone | 256 | 77 |
| Escitalopram Oxalate | Escitalopram Oxalate | 228 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 227 | 64 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 204 | 58 |
| Alendronate Sodium | Alendronate Sodium | 190 | 62 |
| Eliquis | Apixaban | 190 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 188 | 71 |
| Simvastatin | Simvastatin | 182 | 55 |
| Xarelto | Rivaroxaban | 178 | 46 |
| Allopurinol | Allopurinol | 175 | 49 |
| Gabapentin | Gabapentin | 172 | 63 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 170 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 166 | 47 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 145 | 47 |
| Trazodone Hcl | Trazodone Hcl | 142 | 49 |
| Citalopram Hbr | Citalopram Hydrobromide | 141 | 40 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 134 | 36 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 125 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 116 | 43 |
| Glimepiride | Glimepiride | 115 | 34 |
| Metformin Hcl Er | Metformin Hcl | 111 | 32 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 110 | 39 |
| Furosemide | Furosemide | 108 | 34 |
| Meloxicam | Meloxicam | 106 | 31 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 104 | 33 |
| Carvedilol | Carvedilol | 98 | 30 |
| Finasteride | Finasteride | 97 | 30 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 92 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 91 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 88 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 84 | 28 |
| Celecoxib | Celecoxib | 76 | 24 |
| Bupropion Xl | Bupropion Hcl | 73 | 23 |
| Tramadol Hcl | Tramadol Hcl | 72 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 16 |
| Warfarin Sodium | Warfarin Sodium | 61 | 17 |
| Torsemide | Torsemide | 60 | 19 |
| Jardiance | Empagliflozin | 59 | 14 |
| Valsartan | Valsartan | 56 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 52 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 48 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 12 |
| Mirtazapine | Mirtazapine | 44 | 11 |
| Montelukast Sodium | Montelukast Sodium | 44 | 12 |
| Chlorthalidone | Chlorthalidone | 40 | 12 |
| Nitroglycerin | Nitroglycerin | 40 | 26 |
| Potassium Chloride | Potassium Chloride | 40 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 40 | 12 |
| Trulicity | Dulaglutide | 39 | suppressed |
| Famotidine | Famotidine | 36 | 13 |
| Azelastine Hcl | Azelastine Hcl | 29 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Colchicine | Colchicine | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Bumetanide | Bumetanide | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 22 | suppressed |
| Prednisone | Prednisone | 22 | 18 |
| Tolterodine Tartrate | Tolterodine Tartrate | 22 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Alprazolam | Alprazolam | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Jantoven | Warfarin Sodium | 18 | suppressed |
| Ozempic | Semaglutide | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 14 |
| Lovastatin | Lovastatin | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | 13 |
| Clonazepam | Clonazepam | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Novolog | Insulin Aspart | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Losartan Potassium | Losartan Potassium | 13 | suppressed |
| Minoxidil | Minoxidil | 13 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | 11 |
| Wegovy | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,315.04 · 2 records | Baxter Healthcare | Hillrom - ABPM 6100 Blood Pressure Monitor, Hillrom - Blood Pressure Connector, Hillrom - Connex ProBP 3400 Digital Blood Pressure Device, Hillrom - FlexiPort Disposable Blood Pressure Cuffs, Hillrom - Welch Allyn Home Blood Pressure Monitor | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error